Conclusions & Recommendations

TEC acknowledges the need to be opportunistic in implementation of MDA, providing service to approved districts when possible.

TEC commends the National Program and its partners for conducting operational research that clearly illustrated that not reaching nomadic populations was an obstacle to achieving elimination targets.

Given the TF and Ct infection data presented for Ngorongoro, Mpwapwa, Longido, Monduli, and others, TEC encourages the MOH to consider submitting a Zithromax® request for targeted treatment to nomadic populations.

Further, TEC recommends consideration of appropriate strategies to determine the disease burden and effectively reach such populations, as recommended during TEC 15.

TEC recommends to ITI management to offer technical assistance for program and supply chain capacity development in close coordination with the National Program at national and provincial levels.

TEC recognizes there are a number of districts without up-to-date prevalence information, and encourages the Zambian MOH to consider additional surveys in Limulunga and Mongu in Western Province.

TEC further encourages the National Program to submit a Zithromax® request in any districts where future prevalence surveys indicate that treatments are warranted.

TEC encourages the National Program to submit a Zithromax® request to ITI as data become available following baseline surveys in any areas that warrant treatment.

Because Kamaran was not included in surveyed evaluation units, TEC recommends that the 2019 drug decision is “Does not meet Criteria” and that Kamaran be included in the EU for upcoming impact surveys in Al Mighlaf, Al Munirah, As Salif, and Az Zaydiyah in Al Hudaydah.

TEC endorses the Refugee Decision Making Flow Chart presented at TEC 18 and recommends to ITI management to communicate the decision making process to country programs and partners, where relevant.